# Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

> **NCT00313079** · PHASE1 · COMPLETED · sponsor: **Steven E. Coutre** · enrollment: 9 (actual)

## Conditions studied

- Leukemia, Lymphocytic
- Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** MAb 216
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00313079
- **Lead sponsor:** Steven E. Coutre
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-02
- **Final completion:** 2009-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2012-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313079, "Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00313079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*